The detection of abnormal plasma cells (PCs) is a fundamental element in diagnosing plasma cell proliferative disorders (PCPDs) such as multiple myeloma. Flow cytometry (FC) is routinely employed for this purpose; by this method, neoplastic PCs are identified either by restricted patterns of cytoplasmic immunoglobulin (cy-Ig) light chain expression or by aberrant patterns of surface antigen expression. For the latter CD19, CD45 and CD56 are commonly studied based on the observation that abnormal PCs are typically CD56 positive and CD19 and CD45 negative, whereas normal PCs are CD19 and CD45 positive and CD56 negative. 1 Although neoplastic PCs can be identified by either of these FC approaches, both have notable shortcomings. It can be difficult to confidently identify abnormal PCs by cy-Ig light chain restriction alone particularly when the number of cells is low, when they are obscured by a background population of normal polytypic PCs, or when the disorders are bi-clonal with subsets positive for k-and l-Ig light chain, respectively. While the evaluation of surface antigens avoids many of these pitfalls, the surface immunophenotype is not sufficiently distinctive to allow for the malignant PCs to be identified in up to 10% of PCPDs. 2 Furthermore, in all FC analyses it is difficult to formulate a gating strategy which allows for the PCs to be captured, even when real-time (or 'live') gating is used. This problem can be exacerbated when evaluating cy-Ig light chain expression as membrane permeabilization required alters the physical properties of the PCs.
Given these limitations of conventional FC, PC evaluation in the clinical laboratory is often supplemented by slide-based immunohistochemical or immunofluorescence (IF) testing. In our laboratory, slide-based IF is performed in conjunction with FC when assessing peripheral blood (PB) and bone marrow (BM) aspirate specimens for potential involvement by a PCPD. 3 In this assay, mononuclear cells are isolated by Ficoll gradient. Fourcolor FC is then performed using two assay tubes each containing antibodies to CD38 and CD45, which are combined with antibodies to cy-Igk and CD20 in one tube and antibodies to cy-Igl and CD56 in the other. Cy-Ig light chain-restricted PCs are then identified through a CD38 bright, CD45 dim-tonegative gate. Slide-based IF is performed when FC or serum protein studies indicate the presence of cy-Ig light chainrestricted PCs. This second step is used to confirm the presence of monotypic PCs and also to calculate the PC proliferation fraction by measurement of nuclear incorporation of the thymidine analog bromodeoxyuridine.
While the tandem use of FC with slide-based IF achieves the goal of sensitive PC detection, the use of multiple tests is cost and time inefficient and the slide-based IF requires the availability of test-specific reagents at the time of BM aspiration. In an effort to optimize PC detection with the ultimate goal of obviating the need for slide review, a novel FC strategy was devised combining elements of both cy-Ig light chain restriction and aberrant surface antigen expression. In this new method, PCs are stained with antibodies to CD38 (APC), CD138 (PerCPCy5.5), CD19 (PE-Cy7) and CD45 (APC-Cy7); fixed and permeabilized using a commercially available reagent (Caltag, Carlsbad, CA, USA) and then stained with antibodies to cy-Igk (FITC) and cy-Igl (PE). The cells are then analyzed in a singleassay tube (six-color FC) on the recently introduced FACSCanto instrument (Becton Dickinson, San Jose, CA, USA). PCs are identified by gating on cells with moderate-to-bright coexpression of CD38 and CD138 (Figure 1a ) with review of ungated data to ensure that all cy-Ig-positive PCs are included. Cut-offs for antigen positivity and degrees of antigen expression are established by comparison to antibody-fluorochromematched isotype controls. As antibodies to all of the tested antigens are combined, the PCs can be simultaneously analyzed for both cy-Ig light chain restriction and patterns of CD19 and CD45 expression (Figure 1b) , preventing the tube-to-tube variations which can effect the determination of PC monotypia when the cy-Ig light chains are evaluated separately as in the four-color FC approach.
Eighty-eight PB and 160 BM aspirates collected over a 12-month period were analyzed by both the single-tube six-color assay and the combined four-color FC/IF assay and the results were compared ( Table 1 ). The 248 specimens were from 226 patients; the clinical diagnoses were available in 206 specimens and included multiple myeloma (n ¼ 111), primary systemic amyloidosis (n ¼ 36), monoclonal gammopathy of uncertain significance (MGUS) (n ¼ 26), smoldering myeloma (n ¼ 15), POEMS syndrome (n ¼ 6), polyclonal hypergammaglobulinemia (n ¼ 3), localized amyloidoma (n ¼ 3), extramedullary plasmacytoma (n ¼ 2), light chain deposition disease (n ¼ 2) and possible PCPD (n ¼ 2). For the six-color FC, 150 000 events were collected, the assay was considered positive when a CD38 and CD138 co-expressing cell population was identified which demonstrated unequivocal cy-Ig light chain restriction (Igk:Igl ratio410:1 or o1:10; Figure 1a ). Absence of CD19 expression by the cy-Ig light chain-restricted cells was used as a secondary criterion, particularly when there were less than 150 PC events or when the cy-Ig light chain-restricted cells were predominantly CD45 positive. Using these criteria, six-color FC was highly sensitive with the ability to detect as few as 40 abnormal PCs per 150 000 events, or approximately 0.03%. In 17 specimens (nine PB and eight BM), six-color FC detected abnormal PCs that were missed by the combined FC/IF approach. In all of these cases, the cy-Ig light chain expressed by the abnormal PCs was identical to the Ig light chain identified in the serum and/or urine monoclonal protein. In nine cases (six PB and three BM) the six-color FC was considered negative even though abnormal PCs were identified by combined FC/IF. For seven of these nine cases, the nucleated cells for six-color FC were isolated by isotonic RBC lysis rather than Ficoll gradient. When comparing cases in which both assays used Ficoll prepared cells (n ¼ 183), there were only two cases (1%) in which six-color FC failed to detect abnormal PCs identified by combined FC/IF. Conversely, among this group of cases, there were 15 cases (8%) in which six-color FC detected abnormal PCs missed by combined FC/IF. Hence, when controlling for pre-analytical mononuclear cell enrichment, the six-color FC assay was considerably more sensitive than the combined fourcolor FC/IF method.
The superior sensitivity of six-color FC for PC detection was largely attributable to its ability to recognize phenotypic differences in neoplastic PCs that are present both between and within individual cases. Although all of the PCs studied coexpressed CD38 and CD138, the staining intensity for these antigens varied between cases. The expression of CD138 by PCs may be lost ex vivo; however, these differences were seen even when freshly procured PCs were analyzed, indicating many of these variations reflected true phenotypic variability of CD38 and CD138 expression between cases. 4 The observed differences in CD38 and CD138 expression between cases were relatively minor (usually within approximately 0.5-1 log); however, in some instances they interfered with PC identification. This was particularly true for decrements in CD38 expression by the abnormal PCs which frequently led to significant overlap with other CD38-positive cells in the specimens such as normal B precursors (hematogones). In this setting, the inclusion of CD138 was helpful for PC identification and furthermore in this single-tube, multiparameter approach, PCs could still be identified when both CD38 and CD138 staining were not sufficiently distinctive by back-gating on cy-Igpositive cells (data not shown).
In addition to these differences between cases, phenotypically distinct cell subsets were also present within individual Ig light chain-restricted PC populations. This intraclonal phenotypic heterogeneity was most often seen for CD45 expression. CD45 expression by the abnormal PCs was identified in approximately half of the PB cases and in over two-third of the BM cases ( Table 2 ). The CD45 positivity of PCs in six-color FC was not due to the use of an APC-Cy7 tandem conjugate as it was seen with different antibody lots and persisted after post-acquisition compensation correction. In the majority of these cases, distinct CD45 dim-to-negative and CD45-positive Ig light chain PC subsets were present, as demonstrated by selective, sequential gating (Figure 1a and b) . In isolated cases, the abnormal PCs showed a continuum of CD45 expression from negative to positive. In the majority of BM cases with CD45-positive neoplastic PCs, the CD45-negative PC subset predominated (Table 2 and Figure 1 ). However, in many of the PB and in a minority of the BM cases, the proportion of CD45-negative and -positive cells was nearly equal; and in some, the CD45-positive PCs were the predominant PC subset. CD19 expression by the cy-Ig light chain-restricted PCs was detected in a single case.
The frequency of CD45 expression in PCPDs reported in the published literature varies; this may be due to, in part, differences in FC strategies used many of which are inherently biased against the detection of a CD45-positive component. However, even when comparing to our four-color FC/IF data and a large clinical laboratory study using three-color FC to study myelomatous PCs and specifically evaluating for CD45 expression, the degree of PC CD45 expression detected by sixcolor FC was greater than expected. 4 This method-based discrepancy raises the possibility that the six-color FC can detect a minor CD45-positive B-cell component of the PCPDs. However, virtually in all the cases, both the CD45-positive and CD45-negative PC subsets were CD19 negative (Figure 1b) essentially excluding this hypothesis. The single case in which CD19 positivity was detected was an IgM MGUS, suggesting this may represent a true B-cell disorder. 5 Another possibility raised is that the CD45 staining is secondary to adhesion of CD45-positive T cells. To address this, duplicate studies were performed using antibodies to CD3 (in lieu of CD19) in 32 cases containing CD45-positive cy-Ig light chain-restricted PCs. T-cell adhesion in the CD45-positive Ig light chain-restricted PCs was detected in 31 cases but in all the proportion of PC-T-cell aggregates was low (median 10% of the CD45-positive PCs aggregated with CD3-positive T cells, range 0-25%). Furthermore, in duplicate six-color FC analyses performed in 22 cases with CD45-positive PCs (18 BM and 4 PB), the proportion of CD45-positive PCs was relatively constant. Based on these findings it is unlikely that the CD45 expression detected was spurious or a secondary phenomenon. Rather, it appears that CD45-positive abnormal PCs are commonly present in PCPDs and that six-color FC has greater sensitivity in detecting this PC component through the ability to gate through both CD38 and Table 1 Comparison of abnormal PC detection by six-color flow cytometry and combined four-color flow cytometry and immunofluorescence Abbreviations: BM, bone marrow; FC, flow cytometry; PB, peripheral blood; PCs, flow cytometry.
Letters to the Editor
CD138 and to coincidently analyze CD19 and cy-Ig light chain expression. While any immunophenotyping method may in some instances be unable to detect very small monoclonal PC populations for a number of reasons, including sampling bias, the goal is to use a methodology that will minimize the number of cases that fall into this predicament. Hence, the ability of sixcolor FC to rapidly detect abnormal PCs with high sensitivity is a significant advance in laboratory PCPD diagnosis. The accurate detection and delineation of abnormal PC subsets by this method may not only be diagnostically relevant but may also provide information regarding disease biology and prognosis. A number of in vitro studies using normal and myelomatous PCs indicate that bright CD45 expression is seen on the most actively proliferating cells. 6 Yet, these differences have not been confirmed by clinical FC and clinical correlation studies have made the counterintuitive observation that an increased proportion of CD45-positive PCs in PCPDs is associated with a better prognosis. 7, 8 The short follow-up and case mixture in this study prevents correlation between CD45 expression and outcome. However, when comparing the 14 PB cases with CD45-positive abnormal PCs and the 17 PB cases with completely CD45-negative PCs (both of which were comprised similar proportions of treated and untreated myeloma cases), a higher proliferation index in the BM PCs was noted in the CD45-negative group (0.5 vs 0.9). Through more precise characterization of the CD45-positive and CD45-negative abnormal PC compartments, six-color FC and methods derived from it may help reconcile these apparently discrepant observations regarding CD45 and PC proliferation vs disease outcome. Ultimately, the new information generated by the introduction of this powerful technique should enable the clinical laboratory to provide more substantive data to clinicians and thereby improve patient care. Detection of minimal residual disease (MRD) in myeloma is highly predictive of early relapse following treatment. A number of different approaches to myeloma MRD detection are available; these vary widely in sensitivity and cost. Although several studies suggest that detection of neoplastic plasma cells above a level of 0.01% is clinically relevant, [1] [2] [3] [4] [5] [6] MRD studies in B-cell chronic lymphocytic leukemia (CLL) comparing different approaches have demonstrated that methods such as consensusprimer immunoglobulin heavy-chain (IgH) PCR and assessment of light-chain restriction by flow cytometry can detect low levels of disease but the sensitivity is highly variable. Such approaches are least informative when large numbers of polyclonal B cells are present as is typical after high-dose therapy and stem cell transplantation. In this setting, false-negative results may be generated in cases with up to 5% residual disease. Therefore, approaches that can directly quantify the proportion of CLL cells, using either CLL-specific flow cytometry assays or realtime quantitative allele-specific oligonucleotide (RQ-ASO) IgH-PCR are recommended for MRD detection as the sensitivity is not impaired by the presence of polyclonal B cells. 7, 8 In both CLL and myeloma, flow cytometric assessment of MRD may be preferable in practice to RQ-ASO IgH-PCR since a clinically relevant limit of MRD detection can be achieved using a standard antibody panel whereas RQ-ASO IgH-PCR requires the cost and labour-intensive development of patient-specific primers. However, quantitative MRD detection of myeloma plasma cells by flow cytometry is relatively complicated compared to CLL flow cytometric MRD analysis. Myeloma MRD flow cytometry requires at least two markers for plasma cell identification (CD38 and either CD45 or CD138, preferably all three) and some combination of several additional markers to detect phenotypic abnormality including CD19, CD20, CD27, CD28, CD45, CD56 and CD117. [4] [5] [6] 9, 10 As most of the myeloma-associated phenotypic plasma cell abnormalities can also be detected at low levels in healthy individuals, assessment of immunoglobulin light-chain restriction (cytoplasmic k and l) is also informative.
Six-colour flow cytometry offers the opportunity to combine the gating markers CD38/CD138/CD45 with clonality assess-
